Emyria has filed additional patents in support of its cannabinoid-based EMD-004 drug-development program targeting the symptoms of irritable bowel syndrome (IBS).
The new IP was filed after analysis of data collected from consenting patients who obtained relief from IBS while being treated at Emyria’s Emerald Clinics.
A large observational study involving IBS patients is currently underway across the clinic network.
Emyria managing director Dr Michael Winlo said: “A major benefit of Emyria’s high-quality, real-world clinical data is that it allows us to frequently and confidently file differentiated and strongly developed patents that support and defend our parallel-running drug-development programs.”
“Just like EMD-003, our first cannabinoid medicine drug-development program targeting psychological distress, EMD-004 is now well defined with patents filed covering our unique dose response insights for specific patient populations.”
“Filing IP of this kind is crucial in helping differentiate, and ultimately register, cannabinoid-based treatments in major markets around the world. This is what large pharma look for in drug-development programs.
IBS affects around 11% of the population globally and is a significant unmet need often associated with greater levels of anxiety and lower quality of life measures. There are currently no approved drug treatments for IBS.